Summary
We have investigated the pharmacokinetics of the direct vasodilator flosequinan in elderly patients with congestive heart failure. Eight patients received a single dose of 50 mg, and 8 patients received once-daily treatment with 25 mg for two weeks.
In the single dose study, the tmax of flosequinan was 2.5 h, Cmax was 1.17 μg · ml−1 and t1/2 was 5.63 h. The tmax of the metabolite BTS 53554 was 20.3 h, Cmax was 1.44 μg · ml−1 and t1/2 was 62.0 h.
BTS 53554 accumulated gradually in the 14-day repeated dose study and steady-state was reached after approximately 2 weeks. Flosequinan was not found to accumulate.
Adverse reactions were not observed in either the single or repeated dose study.
It is advisable to consider renal function and body weight when flosequinan is to be administered to elderly patients with congestive heart failure. The initial dose should be 25 mg.
This is a preview of subscription content, log in via an institution to check access.
References
Yates DB (1991) Phamacology of flosequinan. Am H J 121: 974–983
Kessler PD, Packer M (1987) Hemodynamic effects of BTS 49465, a new long-acting systemic vasodilator drug, in patients with severe congestive heart failure. Am H J 113: 137–143
Elborn JS, Stanford CF and Nicholls DP (1989) Effect of flosequinan on exercise capacity and symptoms in severe heart failure. Br Heart J 61: 331–335
Parmley WW (1989) Pathophysiology and current therapy of congestive heart failure. J Am Coll Cardiol 13: 771–785
Slegowski MD, Miller C, Porter RS (1988) Simplified high-performance liquid chromtographic determination of flosequinan and its metabolite in plasma, serum and urine. J Chromatogr 425: 227–232
Wagner J (1976) Model-independent linear pharmacokinetics. Drug Intell Clin Pharm 10: 179–180
Gibaldi M, Perrier D (1982) Pharmacokinetics, second edition revised and expanded. Dekker, New York, Basel
Hirosawa K, Kimata S, Takano T, Hori M (1992) The effect of flosequinan (BTS 49465) in patients with heart failure — Hemodynamic effects of a single oral dose. Jpn J Clin Pharmacol Ther 23: 453–467
Hind ID, Wynne RD, McNamara RJ. An open evaluation of the pharmacokinetic and haemodynamic effects of flosequinan, both acutely and after four weeks of treatment, in a group of patients with moderate cardiac failure and a group with severe cardiac failure (Protocol No. CFQ 8020, BOOTS Co., in house data)
Hirosawa K, Kimata S, Takano T, Hori M, Sakurai T (1991) Clinical evaluation of flosequinan (BTS 49465) on chronic heart failure — a multicenter double-blind comparative dose finding study. J Clin Ther Med 7: 1721–1746
Sebe T, Saito S, Nishiuchi T, Odomi M, Kaji K, Shimizu T (1991) Haemodynamics and pharmacokinetics of flosequinan (BTS 49465) after single and multiple oral administration in healthy volunteers. Jpn J Clin Pharmacol 22: 593–600
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sakai, M., Ohkawa, S., Kaku, T. et al. Pharmacokinetics of flosequinan in elderly patients with chronic congestive heart failure. Eur J Clin Pharmacol 44, 387–389 (1993). https://doi.org/10.1007/BF00316479
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00316479